Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $703000.0.

  • Xeris Biopharma Holdings' Change in Receivables rose 15399.39% to $703000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year increase of 36124.69%. This contributed to the annual value of $1.2 million for FY2024, which is 8544.28% down from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Change in Receivables is $703000.0, which was up 15399.39% from $6.7 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Change in Receivables peaked at $15.7 million during Q3 2023, and registered a low of -$6.8 million during Q4 2023.
  • For the 5-year period, Xeris Biopharma Holdings' Change in Receivables averaged around $2.2 million, with its median value being $1.8 million (2022).
  • The largest annual percentage gain for Xeris Biopharma Holdings' Change in Receivables in the last 5 years was 89149.61% (2024), contrasted with its biggest fall of 604333.33% (2024).
  • Xeris Biopharma Holdings' Change in Receivables (Quarter) stood at -$449000.0 in 2021, then surged by 837.64% to $3.3 million in 2022, then plummeted by 304.38% to -$6.8 million in 2023, then surged by 89.32% to -$723000.0 in 2024, then surged by 197.23% to $703000.0 in 2025.
  • Its Change in Receivables was $703000.0 in Q3 2025, compared to $6.7 million in Q2 2025 and $5.9 million in Q1 2025.